I think our lack of good data was a problem for the EU.
Now we should have fda approved, blinded data and lots of it.
The tis timing was unfortunate as there had just been a case of some people dying on a clinical trial - so everybody was being extra cautious. So the approval buck was passed around by the bma, the eu and others.
As for stale holders - good clinical data will clean away them in no time. New money doesn't care about the past imho.
FTT Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held